Stokes Family Office LLC Invests $465,000 in Sanofi (NASDAQ:SNY)

Stokes Family Office LLC acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,635 shares of the company's stock, valued at approximately $465,000.

Other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Sanofi in the fourth quarter valued at $135,933,000. Boston Partners boosted its stake in shares of Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after buying an additional 2,501,073 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock worth $109,753,000 after buying an additional 1,720,972 shares during the last quarter. DAVENPORT & Co LLC grew its holdings in Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock worth $110,715,000 after acquiring an additional 664,455 shares during the period. Finally, Thrivent Financial for Lutherans lifted its holdings in Sanofi by 36.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock valued at $93,774,000 after acquiring an additional 514,542 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Down 1.7 %

NASDAQ:SNY traded down $0.97 on Monday, hitting $55.93. The stock had a trading volume of 1,816,161 shares, compared to its average volume of 2,269,218. The company has a fifty day moving average price of $54.55 and a two-hundred day moving average price of $52.85. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a market cap of $141.94 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 1.01 and a beta of 0.58.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. The Goldman Sachs Group began coverage on shares of Sanofi in a report on Friday. They set a "neutral" rating and a $65.00 target price for the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.